Earnings summaries and quarterly performance for Wellgistics Health.
Research analysts covering Wellgistics Health.
Recent press releases and 8-K filings for WGRX.
Wellgistics Health, Inc. Provides 2026 Corporate Outlook and Announces Convertible Note Offering
WGRX
Guidance Update
Debt Issuance
New Projects/Investments
- Wellgistics Health, Inc. released its 2026 Corporate Outlook, detailing plans to integrate its EinsteinRx™ AI platform and target onboarding up to 500 pharmacies per month into its network by year-end 2026.
- The company will expand manufacturer supplier relationships for products addressing diabetes, weight loss, cardiometabolic, and Long COVID, initially focusing on the SGLT-2 drug Brenzavvy®.
- On January 5, 2026, Wellgistics Health entered into a Note Purchase Agreement for a private offering of up to $3,125,000 in convertible promissory notes, sold for $2,500,000 at a 20% original issue discount.
- These notes carry 0% interest (18% upon default) and are due in six months or upon a Qualified Financing, with a conversion floor price of $0.08 per share.
Jan 8, 2026, 10:25 PM
Wellgistics Health Licenses DataVault AI Patents for Blockchain-Enabled PharmacyChain™
WGRX
New Projects/Investments
Product Launch
- Wellgistics Health, Inc. entered into a License Agreement with DataVault AI Inc. on November 24, 2025, to license intellectual property for its PharmacyChain™ initiative.
- This partnership aims to fully digitize the tracking of prescription drugs from script to fulfillment using blockchain-enabled smart contracts, positioning Wellgistics Health to become a Web 3.0 Health Information Data Transfer Leader in the $634 billion US prescription drug industry.
- Under the agreement, Wellgistics Health will pay DataVault AI a non-refundable license fee of $2,500,000 by December 31, 2025, and a 13% royalty on net profit received from the license.
- A minimum annual royalty of $1,000,000 will be required starting in 2028, provided Wellgistics Health achieves at least $2,000,000 in annual net profit from PharmacyChain™ for 2028 and 2029.
Nov 25, 2025, 10:00 PM
Wellgistics Health Reports Q3 2025 Financial Results and Business Updates
WGRX
Earnings
CEO Change
Product Launch
- Wellgistics Health reported a net operating loss of $33.878 million for the third quarter of 2025, compared to a net operating loss of $1.867 million in the third quarter of 2024, primarily due to increased stock-based compensation.
- The company's net loss per share for Q3 2025 was $0.46 on 74.379 million weighted average shares outstanding, compared to a net loss of $0.04 per share on 48.403 million weighted average shares outstanding in Q3 2024.
- Prashant Patel was reappointed President and named Interim-CEO on October 6, 2025.
- Wellgistics Health is focusing its sales team on the launch of Brenzavvy® for the Type 2 diabetes market, leveraging its EinsteinRx™ AI pharmacy hub software, which is now ready for launch.
- The previously disclosed acquisition of Peek Healthcare Technologies, Inc. has been terminated as it no longer strategically aligns with the company's plans.
Nov 20, 2025, 9:35 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more